The Flow Cytometry Core Facility Experience - ELRIGelrig.org/downloads/fci14/PFC14-DDavies.pdf ·...
Transcript of The Flow Cytometry Core Facility Experience - ELRIGelrig.org/downloads/fci14/PFC14-DDavies.pdf ·...
The Flow Cytometry Core Facility Experience
Derek Davies London Research Ins�tute
ELRIG Pharmaceu�cal Flow Cytometry 2014
The Flow Cytometry Core Facility Experience
� Establishment, growth and success � Benefits of centralisa�on � Challenges for management � Metrics of success � Adding value
The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been
the red x still appears, you may have to delete the image and then insert it again.
0 101 102 103RFP
0
101
102
103
GFP
0 200 400 600 800 1000Propidium Iodide
100
101
102
103
104
Anti-
phos
phoH
3
100 101 102 103 104
Annexin V-FITC
100
101
102
103
104
Pro
pidi
um Io
dide
ELRIG Pharmaceu�cal Flow Cytometry 2014
Why is (flow) cytometry important?
0
2000
4000
6000
8000
10000
12000
1 4 7 10 13 16 19 22 25 28 31 34 37 40
Number
Year
Flow cytometry publica�ons 1975-‐2013
ELRIG Pharmaceu�cal Flow Cytometry 2014
Centralises the hardware Centralises the exper�se
Why is a core cytometry facility important?
It’s self evident but do we want to get there and, if so, how?
ELRIG Pharmaceu�cal Flow Cytometry 2014
Let’s talk about me…
� Established core facility � Started mid 1980’s � Strong culture of development � Large staff level � Proac�ve internally � Proac�ve externally � Courses � Mee�ngs � Collabora�on
ELRIG Pharmaceu�cal Flow Cytometry 2014
Appropriate staff level
The same old user level
Appropriate hardware level
… to today
ELRIG Pharmaceu�cal Flow Cytometry 2014
Idea Product
This is what we do…
Advice and assay design
Training
Cytometer opera�on
Analysis and interpreta�on
Future planning
ELRIG Pharmaceu�cal Flow Cytometry 2014
Line Manager User Group
Core Manager
Budget Control
Service Charges
Technology awareness and evalua�on
Advice to Lab Users
Adver�sement
Ancillary services
Technical development
Data control
User training and supervision
Cell sorter opera�on
Analy�cal cytometer opera�on
Supervision and career development
Facility Staff
User Base
This is what we do…
� Natural resistance to change
� No clear benefit
� May need new skills/techniques
� Self interest
� Fear of the unknown
� Perceived as a risk
How can we go about this? There are hurdles to overcome…
ELRIG Pharmaceu�cal Flow Cytometry 2014
� Process is never passive, all par�es take an ac�ve role � Change driven internally
� Innova�on � Users needs � Improvement � Efficiency
� Change driven externally
� Regula�ons � Organisa�on � Equipment obsolescence
How can we go about this? There are hurdles to overcome…
ELRIG Pharmaceu�cal Flow Cytometry 2014
• Analy�cal Technology: What is needed to cover Lab remit? • Sor�ng Technology: Is it required? If so, what? • Clinical Applica�ons: Will flow cytometry technology be used for IVD
• Will Lab need cer�fica�on? CLP? GLP? GMP? • Future Laboratory Requirements: Will you need to “grow” the facility? Addi�onal hardware? New technologies?
What should the Core Lab provide?
How can we go about this?
ELRIG Pharmaceu�cal Flow Cytometry 2014
• General Laboratory environment / Health and Safety
• Business planning
• Opera�onal issues
• Staffing and staff reten�on
Not all considera�ons are cytometry-‐related
How can we go about this?
ELRIG Pharmaceu�cal Flow Cytometry 2014
� Direct funding � Own grant wri�ng
� Fee for service � PAYG
� Contracted
Where does funding come from?
ELRIG Pharmaceu�cal Flow Cytometry 2014
User Support: Training and supervision of Users
Hands-‐on support for new users Support for Experienced Users -‐ Advanced Data Acquisi�on -‐ Advanced Troubleshoo�ng
Experimental Design Consulta�on -‐ Basic Sample Prepara�on -‐ Fluorescent Reagent Choice -‐ Experimental analysis
Tasks performed by Staff
ELRIG Pharmaceu�cal Flow Cytometry 2014
� Self evalua�on – do we provide what users want? � How accessible are the services? � How welcoming is the environment? � Partners not customers � Add value � Teaching important as it expands knowledge
Opera�onal considera�ons
Constant monitoring of service provision
ELRIG Pharmaceu�cal Flow Cytometry 2014
� Be efficient (and make sure efficiencies are seen) � Staff development and reten�on � Ensure quality � Plan for the future � Re-‐invest � Open door policy
Opera�onal considera�ons
Constant monitoring of service provision
ELRIG Pharmaceu�cal Flow Cytometry 2014
� Robust research � New and emerging technologies � R&D
Opera�onal considera�ons
Constant monitoring of service provision
Mission statement and vision “Cu�ng edge technology and development, integra�ng with, and adding value to, research.”
Research is a risky business – need to manage risk
ELRIG Pharmaceu�cal Flow Cytometry 2014
Usage tracking:
0
50
100
150
200
250
300
350
400
450
500
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57
Month
Hours
Plateau indicates max capacity or max usage
More machines or more users!
Metrics of success
ELRIG Pharmaceu�cal Flow Cytometry 2014
Sorter 2 Sorter 3
0 5 10 15 20 25
Phenotyping: Thymo
Phenotyping: Cultured cells
Phenotyping: B/T cells
Phenotyping: Other
Fluorescent Proteins
Asceptic Sorting
Sorting for microarray
Sorting for RNA
DNA analysis
Apoptosis Analysis
BrdU Analysis
Development
Usage can show when new equipment needed and allows targe�ng of the right people.
0
20
40
60
80
100
120
1 9 17 25 33 41 49 57 65 73 81 89 97 105 113 121 129 137 145 153 161 169 177 185
Metrics of success
ELRIG Pharmaceu�cal Flow Cytometry 2014
Surveys
What the facility does well
What it does not so well
Use several methods
Talk to users!
Customer sa�sfac�on
Keep up the good work
ELRIG Pharmaceu�cal Flow Cytometry 2014
Interac�on with users
Go to Lab mee�ngs and seminars
Be accessible, go walkabout, drink coffee
Become involved with the science
Interac�on with other cores
Go to conferences with cytometry content
Business cards with mul�ple contacts
Core Heads Group especially allied technologies
Keep up the good work
ELRIG Pharmaceu�cal Flow Cytometry 2014
Cer�fica�on SOPs ISO9001 ICCE ISAC SRL
GxP – 21CFR
Keep up the good work
ELRIG Pharmaceu�cal Flow Cytometry 2014
Cancer Chromosomes DNA replica�on DNA repair Vascular Biology Cell signalling Stem Cells Immunity Structural Biology
Human Health Developmental Biology Neurobiology Immunity and infec�on Immunoregula�on Mycobacteria Parasitology Physiology Virology
Drug development HTS Chemistry Others?
Challenges for the future
ELRIG Pharmaceu�cal Flow Cytometry 2014
New hardware
Be�er training Be�er educa�on
New technology
Challenges for the future
ELRIG Pharmaceu�cal Flow Cytometry 2014
Summary
What can centralisa�on add?
� The ability to get moving using established technology � The ability to introduce techniques using experienced staff who understand the technology
� Be at the forefront of newer developments by being seen as expert by manufacturers
� Introduc�on and awareness of current Best Prac�ces
ELRIG Pharmaceu�cal Flow Cytometry 2014